Literature DB >> 3154317

Effect of mexiletine, amiodarone and disopyramide on the excitability and refractoriness of canine cardiac fibers: possible relation to antiarrhythmic drug action and classification.

Y Nakaya1, V Elharrar, B Surawicz.   

Abstract

We tested the hypothesis of Campbell that the effect of the sodium channel-blocking antiarrhythmic drugs on postrepolarization refractoriness i.e., relation between action potential duration (APD) and effective refractory period (ERP) is determined by the drug's effect on the recovery from Vmax block. We studied the effects of two antiarrhythmic drugs with fast (mexiletine, amiodarone), and one with slow (disopyramide) kinetics of recovery from Vmax block, at two different basic cycle lengths (BCL), on ERP/APD ratio in cardiac dog Purkinje and ventricular muscle fibers. ERP was measured using stimuli of 2 ms duration and 1.0 to 5.0 times diastolic threshold strength. The three drugs altered the kinetics of recovery from Vmax block in the manner previously reported by us and other investigators. In both fiber types, mexiletine increased and the other two drugs did not change the ERP/APD ratio. We concluded that the magnitude of postrepolarization refractoriness could not be predicted from the kinetics of the Vmax block. Also, the effect of the drug on the ERP/APD ratio could be altered by changes in the stimulus strength and the BCL.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3154317     DOI: 10.1007/bf02125467

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  26 in total

1.  Disopyramide.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1979-04-26       Impact factor: 91.245

2.  Pharmacodynamics of intravenous amiodarone in the dog.

Authors:  S J Connolly; R Latini; R E Kates
Journal:  J Cardiovasc Pharmacol       Date:  1984 May-Jun       Impact factor: 3.105

3.  Effect of antiarrhythmic drugs on the premature action potential duration in canine cardiac Purkinje fibers.

Authors:  A Varro; V Elharrar; B Surawicz
Journal:  J Pharmacol Exp Ther       Date:  1985-05       Impact factor: 4.030

4.  Use-dependent effects of amiodarone on Vmax in cardiac Purkinje and ventricular muscle fibers.

Authors:  A Varro; Y Nakaya; V Elharrar; B Surawicz
Journal:  Eur J Pharmacol       Date:  1985-06-19       Impact factor: 4.432

5.  Termination of ventricular tachycardia with ventricular stimulation: salutary effect of increased current strength.

Authors:  H L Waxman; M E Cain; A M Greenspan; M E Josephson
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

6.  Electrophysiological actions of mexiletine (Kö1173) on canine Purkinje fibres and ventricular muscle.

Authors:  M Arita; M Goto; Y Nagamoto; T Saikawa
Journal:  Br J Pharmacol       Date:  1979-09       Impact factor: 8.739

7.  Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone.

Authors:  J W Mason; L M Hondeghem; B G Katzung
Journal:  Circ Res       Date:  1984-09       Impact factor: 17.367

8.  Strength-interval relation in the human ventricle: effect of procainamide.

Authors:  J S Camardo; A M Greenspan; L N Horowitz; S R Spielman; M E Josephson
Journal:  Am J Cardiol       Date:  1980-04       Impact factor: 2.778

9.  Effects of mexiletine on steady-state characteristics and recovery kinetics of V max and conduction velocity in guinea pig myocardium.

Authors:  S Hohnloser; J Weirich; H Antoni
Journal:  J Cardiovasc Pharmacol       Date:  1982 Mar-Apr       Impact factor: 3.105

10.  Electrophysiological actions of mexiletine on isolated rabbit atria and canine ventricular muscle and purkinje fibres.

Authors:  I Yamaguchi; B N Singh; W J Mandel
Journal:  Cardiovasc Res       Date:  1979-05       Impact factor: 10.787

View more
  1 in total

Review 1.  Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST.

Authors:  T J Campbell
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.